{"id":53153,"date":"2023-01-20T19:02:27","date_gmt":"2023-01-20T18:02:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/"},"modified":"2023-01-20T19:02:27","modified_gmt":"2023-01-20T18:02:27","slug":"iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/","title":{"rendered":"Iran Anti-Rheumatic Drug Market Analysis Report 2022: A $2+ Billion Market by 2027 Featuring GlaxoSmithKline, F. Hoffmann-La Roche, & Novartis – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Iran Anti-Rheumatic Drug Market – Forecasts from 2022 to 2027”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nIran’s antirheumatic drugs market was evaluated at US$1,645.313 million in the year 2020, growing at a CAGR of 3.16% reaching the market size of US$ 2,045.699 million by the year 2027.\n<\/p>\n

\nWarm, swollen, & painful joints are symptoms of the medical illness rheumatoid arthritis. The illness primarily affects a person’s hands and wrists. Pain is a symptom of this medical disease, and it gets worse over time. Different medications, referred to as anti-rheumatics, are used to treat this illness.\n<\/p>\n

\nAdditionally, these medications are utilized to alter the course of the illness. For instance, anti-rheumatic medications that reduce the progression of the disease include disease-modifying anti-rheumatics drugs. Additionally, medications such as non-steroidal anti-inflammatory medicines are used to treat rheumatoid arthritis.\n<\/p>\n

\nThe market for antirheumatic drugs in Iran is projected to grow on account of the high prevalence of rheumatoid arthritis in the country, along with the presence of a considerably high proportion of the geriatric population in the country. Furthermore, the rising incidence of cardiovascular diseases in the country is also anticipated to be one of the key factors supplementing the market growth in the country during the next five years.\n<\/p>\n

\nAlso, the burden of CVD will increase by more than double the rate in 2005 by 2025. Additionally, the high number of cases in the country with active malaria foci is also anticipated to bolster the demand for antirheumatic drugs, thereby positively impacting the market growth during the next five years. For instance, according to a report from the World Health Organization, the number of people living with active foci was more than 340,000 in 2017.\n<\/p>\n

\nFurthermore, the rising participation of domestic pharmaceutical companies in the form of growing investments in pharma R&D for the development of numerous high-cost drugs domestically to tap the potential of the market that it holds also widens up the opportunities for the market to grow during the next five years.\n<\/p>\n

\nIran’s antirheumatic drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis, rheumatoid arthritis, gout, lupus, and others. By type of molecule, the Iran antirheumatic drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).\n<\/p>\n

\nThe rheumatoid arthritis sector is predicted to hold a significant market share depending on the type of disease. The industry for rheumatoid arthritis treatment is fueled by the rising prevalence of arthritis and associated joint issues. In addition, the development of rheumatoid arthritis is attributed to a change toward an unhealthy lifestyle, an increase in metabolic diseases and age, a family history of joint disorders, and an increase in obesity. Furthermore, improvements in biosimilar and innovative biologics are anticipated to open up new business prospects in the sector.\n<\/p>\n

\nDue to the rise in the number of specialist hospitals needed to treat the medical condition, the prescription-based drug segment held the biggest share of the market by sales channel. Additionally, due to increased awareness of the rheumatoid arthritis treatment choices, the over-the-counter medicine sector is anticipated to grow at the quickest rate during the projection period. Another important element driving the expansion of the anti-rheumatics business is the simple accessibility of over-the-counter NSAIDs.\n<\/p>\n

\nKey Topics Covered:<\/strong>\n<\/p>\n

\n1. Introduction<\/strong>\n<\/p>\n

\n2. Research Methodology<\/strong>\n<\/p>\n

\n2.1. Research Data\n<\/p>\n

\n2.2. Assumptions\n<\/p>\n

\n3. Executive Summary<\/strong>\n<\/p>\n

\n3.1. Research Highlights\n<\/p>\n

\n4. Market Dynamics<\/strong>\n<\/p>\n

\n4.1. Market Drivers\n<\/p>\n

\n4.2. Market Restraints\n<\/p>\n

\n4.3. Porter’s Five Forces Analysis\n<\/p>\n

\n4.4. Industry Value Chain Analysis\n<\/p>\n

\n5. Iran Antirheumatic Drug Market Analysis, By Type of Disease<\/strong>\n<\/p>\n

\n5.1. Introduction\n<\/p>\n

\n5.2. Osteoarthritis\n<\/p>\n

\n5.3. Rheumatoid Arthritis\n<\/p>\n

\n5.4. Gout\n<\/p>\n

\n5.5. Lupus\n<\/p>\n

\n5.6. Others\n<\/p>\n

\n6. Iran Antirheumatic Drug Market Analysis, By Type of Molecule<\/strong>\n<\/p>\n

\n6.1. Introduction\n<\/p>\n

\n6.2. Pharmaceuticals\n<\/p>\n

\n6.3. Biopharmaceuticals\n<\/p>\n

\n7. Iran Antirheumatic Drug Market Analysis, By Sales Channel<\/strong>\n<\/p>\n

\n7.1. Introduction\n<\/p>\n

\n7.2. Prescription\n<\/p>\n

\n7.3. Over-The-Counter (OTC)\n<\/p>\n

\n8. Competitive Environment and Analysis<\/strong>\n<\/p>\n

\n8.1. Major Players and Strategy Analysis\n<\/p>\n

\n8.2. Emerging Players and Market Lucrativeness\n<\/p>\n

\n8.3. Mergers, Acquisitions, Agreements, and Collaborations\n<\/p>\n

\n8.4. Vendor Competitiveness Matrix\n<\/p>\n

\n9. Company Profiles<\/strong>\n<\/p>\n

\n9.1. GlaxoSmithKline plc\n<\/p>\n

\n9.2. F. Hoffmann-La Roche Ltd\n<\/p>\n

\n9.3. Novartis\n<\/p>\n

\nFor more information about this report visit https:\/\/www.researchandmarkets.com\/r\/usngev<\/a>\n<\/p>\n

\nAbout ResearchAndMarkets.com<\/strong>\n<\/p>\n

\nResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nResearchAndMarkets.com
\n
Laura Wood, Senior Press Manager
\n
press@researchandmarkets.com<\/a>\n<\/p>\n

\nFor E.S.T Office Hours Call 1-917-300-0470
\n
For U.S.\/ CAN Toll Free Call 1-800-526-8630
\n
For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

DUBLIN–(BUSINESS WIRE)–The “Iran Anti-Rheumatic Drug Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering. Iran’s antirheumatic drugs market was evaluated at US$1,645.313 million in the year 2020, growing at a CAGR of 3.16% reaching the market size of US$ 2,045.699 million by the year 2027. Warm, swollen, & painful joints … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53153","6":"format-standard","7":"category-industry"},"yoast_head":"\nIran Anti-Rheumatic Drug Market Analysis Report 2022: A $2+ Billion Market by 2027 Featuring GlaxoSmithKline, F. Hoffmann-La Roche, & Novartis - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iran Anti-Rheumatic Drug Market Analysis Report 2022: A $2+ Billion Market by 2027 Featuring GlaxoSmithKline, F. Hoffmann-La Roche, & Novartis - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN–(BUSINESS WIRE)–The “Iran Anti-Rheumatic Drug Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering. Iran’s antirheumatic drugs market was evaluated at US$1,645.313 million in the year 2020, growing at a CAGR of 3.16% reaching the market size of US$ 2,045.699 million by the year 2027. Warm, swollen, & painful joints ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-20T18:02:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230120005423\/en\/1691913\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Iran Anti-Rheumatic Drug Market Analysis Report 2022: A $2+ Billion Market by 2027 Featuring GlaxoSmithKline, F. Hoffmann-La Roche, & Novartis – ResearchAndMarkets.com\",\"datePublished\":\"2023-01-20T18:02:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\\\/\"},\"wordCount\":776,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230120005423\\\/en\\\/1691913\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\\\/\",\"name\":\"Iran Anti-Rheumatic Drug Market Analysis Report 2022: A $2+ Billion Market by 2027 Featuring GlaxoSmithKline, F. Hoffmann-La Roche, & Novartis - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230120005423\\\/en\\\/1691913\\\/21\\\/logo.jpg\",\"datePublished\":\"2023-01-20T18:02:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230120005423\\\/en\\\/1691913\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230120005423\\\/en\\\/1691913\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iran Anti-Rheumatic Drug Market Analysis Report 2022: A $2+ Billion Market by 2027 Featuring GlaxoSmithKline, F. Hoffmann-La Roche, & Novartis – ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iran Anti-Rheumatic Drug Market Analysis Report 2022: A $2+ Billion Market by 2027 Featuring GlaxoSmithKline, F. Hoffmann-La Roche, & Novartis - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Iran Anti-Rheumatic Drug Market Analysis Report 2022: A $2+ Billion Market by 2027 Featuring GlaxoSmithKline, F. Hoffmann-La Roche, & Novartis - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN–(BUSINESS WIRE)–The “Iran Anti-Rheumatic Drug Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering. Iran’s antirheumatic drugs market was evaluated at US$1,645.313 million in the year 2020, growing at a CAGR of 3.16% reaching the market size of US$ 2,045.699 million by the year 2027. Warm, swollen, & painful joints ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-20T18:02:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230120005423\/en\/1691913\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Iran Anti-Rheumatic Drug Market Analysis Report 2022: A $2+ Billion Market by 2027 Featuring GlaxoSmithKline, F. Hoffmann-La Roche, & Novartis – ResearchAndMarkets.com","datePublished":"2023-01-20T18:02:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/"},"wordCount":776,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230120005423\/en\/1691913\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/","name":"Iran Anti-Rheumatic Drug Market Analysis Report 2022: A $2+ Billion Market by 2027 Featuring GlaxoSmithKline, F. Hoffmann-La Roche, & Novartis - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230120005423\/en\/1691913\/21\/logo.jpg","datePublished":"2023-01-20T18:02:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230120005423\/en\/1691913\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230120005423\/en\/1691913\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/iran-anti-rheumatic-drug-market-analysis-report-2022-a-2-billion-market-by-2027-featuring-glaxosmithkline-f-hoffmann-la-roche-novartis-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Iran Anti-Rheumatic Drug Market Analysis Report 2022: A $2+ Billion Market by 2027 Featuring GlaxoSmithKline, F. Hoffmann-La Roche, & Novartis – ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53153"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53153\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}